Navigation Links
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
Date:11/19/2008

HAYWARD, Calif., Nov. 19 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biotechnology company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced that it has closed the final tranche of its Series A financing. Frazier Healthcare Ventures and Alta Partners co-led the $16.7 million tranche, which also included existing investors Burrill & Company, Three Arch Partners, and Altitude Life Science Ventures. This financing completes the Series A round, bringing the total amount raised to date to over $51 million.

"This financing provides substantial funding for Arete as we look toward the initiation of our Phase II clinical trial in the first quarter of 2009 using AR9281 for the treatment of metabolic syndrome," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "We appreciate our investors' continued commitment to the value of our s-EH inhibitor platform."

"In the last six months, Arete successfully completed a Phase I clinical trials' program for AR9281, expanded its executive management team and completed extensive preclinical studies of s-EH inhibitors," stated James Topper, M.D., Ph.D., Chairman of the Board of Arete Therapeutics and General Partner of Frazier Healthcare Ventures. "Arete's extensive proprietary position in s-EH inhibitors, together with its efficient, focused drug discovery and development organization, position the Company to address the growing healthcare epidemic of metabolic syndrome and identify new therapeutics for cardiovascular and inflammatory disease."

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat metabolic, inflammatory and cardiovascular disease. It is the world's leading company focused on s-EH (soluble epoxide hydrolase), an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company was founded by Dr. Bruce Hammock, a Professor at the University of California, Davis, who discovered s-EH. For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arete Therapeutics Bolsters Management Team
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
4. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
5. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
9. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
10. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
11. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... York , March 23, 2017 According ... plasma products and derivatives market is fragmented due to the presence of ... such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with ... these three companies, collectively, held more than 76% of this market ... As ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
Breaking Biology News(10 mins):